Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03187207 · 1 trial · 2 indications
Intraocular pressure (IOP) was measured using a Goldmann applanation tonometer. Diurnal IOP, defined as the mean IOP over the day based on values obtained at 8 AM, 10 AM, 1 PM, and 4 PM, was calculated for each visit. Both eyes were tested, with the right eye preceding the left eye. The operator initially set the dial at 10 mmHg, then looked through the slit lamp and adjusted the dial to take the reading, and then recorded the results. The procedure was repeated on the same eye twice consecutively. If the measurements were within 2 mmHg or less of each other, the mean of the 2 readings was recorded as the IOP at that time point. If the 2 readings were more than 2 mmHg of each other, a third (consecutive) reading was taken and the median (middle) IOP was recorded as the IOP at that time point.
| Arm | Type | Description |
|---|---|---|
| PF-03187207 High Dose and Latanoprost Vehicle | EXPERIMENTAL | A single drop of each, once daily in study eye for 28 days |
| Latanoprost 0.005% and PF-03187207 Vehicle | EXPERIMENTAL | A single drop of each, once daily in study eye for 28 days |
| PF-03187207 Medium Dose and Latanoprost Vehicle | EXPERIMENTAL | A single drop of each, once daily in study eye for 28 days |
| PF-03187207 Low Dose and Latanoprost Vehicle | EXPERIMENTAL | A single drop of each, once daily in study eye for 28 days |
| Name | Type | Description |
|---|---|---|
| PF-03187207 | DRUG | - |
| Latanoprost 0.005% | DRUG | - |
| PF-03187207 Vehicle | DRUG | One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207. |
| Latanoprost Vehicle | DRUG | - |
Inclusion Criteria: * Man or woman at least 20 years of age * Diagnosis of primary open-angle glaucoma or ocular hypertension in one or both eyes. Exclusion Criteria: * Closed/barely open anterior chamber angle or a history of acute angle closure in either eye * Contraindications to latanoprost a...
PF-03187207 is an investigational small molecule being developed by Bausch + Lomb Corporation for Primary Open Angle Glaucoma. It has been studied in a Phase 2 dose-finding trial that also enrolled patients with ocular hypertension. It is not an approved product and remains in clinical development.
PF-03187207 is being studied for the treatment of Primary Open Angle Glaucoma, a condition in which elevated pressure within the eye can damage the optic nerve. The Phase 2 trial of PF-03187207 also enrolled patients with ocular hypertension, a related condition of raised intraocular pressure.
PF-03187207 is being developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company sponsored the Phase 2 dose-finding study of the compound in patients with Primary Open Angle Glaucoma or ocular hypertension.
PF-03187207 is in Phase 2 development. A Phase 2 dose-finding study in patients with Primary Open Angle Glaucoma or ocular hypertension has been completed. The drug is investigational and has not been approved for any indication.
PF-03187207 has been evaluated in one clinical trial, NCT00595101, titled a Phase 2 dose-finding study of PF-03187207 in patients with Primary Open Angle Glaucoma or ocular hypertension. The trial was completed, enrolled 117 patients, was randomized, double-blind, and controlled, and was conducted in Japan.